The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.
Omburtamab BLA for Pediatric Metastatic Neuroblastoma Resubmitted to FDAApril 1st 2022
A biologics license application seeking the approval of 131I-omburtamab in the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been resubmitted to the FDA.
Targeted Combo Notches Rare Success in GlioblastomaMarch 30th 2022
Encouraging response rates to a dual-targeted regimen in patients with recurrent or refractory malignant brain tumors with BRAF V600E mutations were reported in 2021, representing a new potential targeted therapy strategy against glioblastoma.
Adjuvant Neratinib Misses Primary End Point of OS in Glioblastoma, But Significantly Prolongs PFS in EGFR+ Subset
A subset of patients with EGFR-positive glioblastoma experienced significantly longer progression-free survival when treated with adjuvant neratinib following chemoradiation vs adjuvant temozolomide alone, although no overall PFS benefit or any overall survival improvement was seen in the overall population.
GLORIA Trial Examining NOX-A12 Plus Radiotherapy/Bevacizumab in Glioblastoma Safe to Continue RecruitmentJanuary 11th 2022
The Data Safety Monitoring Board has determined that it is safe and appropriate to continue recruitment to the expansion arm of the phase 1/2 GLORIA trial, which is examining a novel combination comprised of NOX-A12, radiotherapy, and bevacizumab in glioblastoma and incomplete tumor resection.
Activating the Immune System Could be Key to Treating Pediatric NeuroblastomaJanuary 11th 2022
Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma, and the humanized anti-disialoganglioside monoclonal antibody hu14.18K322A could provide a breakthrough for children with high-risk disease.
FDA Grants Rare Pediatric Disease Designation to 177Lu-Omburtamab-DTPA for MedulloblastomaOctober 8th 2021
The FDA has granted a rare pediatric disease designation to lutetium-177-omburtamab-DTPA for use as a potential therapeutic option in pediatric patients with medulloblastoma, according to an announcement from Y-mAbs Therapeutics, Inc., the developer of the product.
Silmitasertib Gets Fast Track Status for Recurrent Sonic Hedgehog–Driven MedulloblastomaAugust 25th 2021
The FDA has granted a fast track designation to the highly selective CK2 inhibitor silmitasertib as a potential therapeutic option for patients with recurrent sonic hedgehog–driven medulloblastoma
Immunotherapy Is on the Rise in Glioblastoma TreatmentJune 23rd 2021
The University of Texas MD Anderson Cancer Center is pursuing several novel approaches, including viro-immunotherapy and genetically engineered natural killer cells to treat patients with glioblastoma, while also conducting tumor analysis to better comprehend the disease.
Oncolytic Virus Teserpaturev Approved in Japan for Malignant GliomaJune 11th 2021
The Japan Ministry of Health, Labour, and Welfare has granted conditional and time-limited approval to teserpaturev for the treatment of patients with malignant glioma; this is the first oncolytic virus to receive approval for use in this indication or any primary brain cancer.
Modified RANO Affords a More Accurate Assessment of Outcomes in Recurrent GlioblastomaMay 26th 2021
Standard response assessment in neuro-oncology- and immunotherapy RANO-defined progression-free did not correlate with overall survival vs modified RANO-defined PFS, which strongly correlated with OS in patients with recurrent glioblastoma treated with MDNA55 in a phase 2 trial, suggesting that mRANO may be the optimal means of therapeutic response assessment in recurrent glioblastoma.
Radiation Strategies Blaze a Trail for Better Outcomes in CNS Cancers and BeyondMay 21st 2021
Stephanie E. Weiss, MD, FASTRO and Eric M. Horwitz, MD, FABS, FASTRO, discuss ways to leverage radiation in the treatment of central nervous system metastases, areas of active investigation, and different available strategies that are improving outcomes for patients with cancer.
cfMeDIP-seq Provides Opportunity for Early Cancer Detection, Classification, and MonitoringMay 18th 2021
Cell-free methylated DNA immunoprecipitation-sequencing uses plasma cell-free methylomes to detect and classify several types of cancer early on, and provides the opportunity to monitor tumors for response to treatment in noninvasive way.
NKT Cells Co-Expressing GD2-CAR, IL-15 Can Induce Complete Remissions in Pediatric NeuroblastomaMay 15th 2021
Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.
FDA Grants Rare Pediatric Disease Designation to WP1066 for EpendymomaApril 14th 2021
The FDA has granted a rare pediatric disease designation to the p-STAT3 inhibitor WP1066 for the treatment of patients with ependymoma, a rare type of tumor that can develop in the brain or the spinal cord.
Dabrafenib Plus Trametinib Provides Benefit Across Glioma SubtypesApril 12th 2021
Dual inhibition of the MAPK pathway using the BRAF and MEK inhibitors dabrafenib and trametinib, respectively, resulted in durable clinical benefit for patients with BRAF V600E mutant low- and high-grade glioma.
FDA Recommends Termination of Phase 2 Trial Examining Immunotherapy ERC1671 in GlioblastomaApril 7th 2021
The FDA has recommended the early termination of a phase 2 trial examining the cell-based immunotherapy ERC1671 in combination with granulocyte-macrophage colony-stimulating factor, cyclophosphamide, and bevacizumab in patients with glioblastoma.
Zotiraciclib Plus Temozolomide Shows Meaningful Efficacy in Recurrent High-Grade GliomasFebruary 5th 2021
February 5, 2021 - The potent CDK9 inhibitor zotiraciclib, when used in combination was temozolomide, was found to induce clinically meaningful efficacy with a tolerable safety profile in patients with recurrent, high-grade gliomas.
FDA Grants 3 Rare Pediatric Disease Designations to STAT3 Inhibitor WP1066January 7th 2021
January 7, 2020 - The FDA has approved the request submitted by Moleculin Biotech, Inc. for rare disease designations to be granted their drug candidate WP1066, an agent that appears to directly elicit tumor cell death and rouse the immune system to eliminate tumors.
Japanese Approval Sought for Oncolytic Virus Teserpaturev for Malignant GliomaJanuary 5th 2021
January 5, 2020 - A new drug application has been submitted to Japan’s Ministry of Health, Labour, and Welfare for the oncolytic virus teserpaturev for use in the treatment of patients with malignant glioma.